AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 14, 2022

Primary Completion Date

December 19, 2023

Study Completion Date

December 19, 2023

Conditions

Higher Risk Myelodysplastic SyndromeChronic Myelomonocytic Leukemia

Interventions

DRUG

AMG 176

Administered as an intravenous (IV) infusion.

DRUG

Azacitidine

Administered as an IV infusion or subcutaneous (SC) injection.

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston